S&P 500   4,443.84 (-0.26%)
DOW   34,923.68 (+0.36%)
QQQ   369.69 (-0.98%)
AAPL   145.06 (-1.27%)
MSFT   293.69 (-1.89%)
FB   351.48 (-0.42%)
GOOGL   2,824.56 (-0.69%)
TSLA   794.40 (+2.58%)
AMZN   3,379.81 (-1.33%)
NVDA   215.16 (-2.56%)
BABA   148.24 (+2.18%)
NIO   36.35 (+2.74%)
CGC   14.72 (+5.82%)
GE   105.97 (+2.09%)
MU   75.15 (+1.49%)
AMD   107.42 (+1.53%)
T   27.59 (+1.70%)
F   14.25 (+3.41%)
ACB   6.38 (+7.23%)
DIS   179.10 (+1.76%)
PFE   43.77 (-0.39%)
BA   225.94 (+2.06%)
BAC   43.38 (+2.94%)
S&P 500   4,443.84 (-0.26%)
DOW   34,923.68 (+0.36%)
QQQ   369.69 (-0.98%)
AAPL   145.06 (-1.27%)
MSFT   293.69 (-1.89%)
FB   351.48 (-0.42%)
GOOGL   2,824.56 (-0.69%)
TSLA   794.40 (+2.58%)
AMZN   3,379.81 (-1.33%)
NVDA   215.16 (-2.56%)
BABA   148.24 (+2.18%)
NIO   36.35 (+2.74%)
CGC   14.72 (+5.82%)
GE   105.97 (+2.09%)
MU   75.15 (+1.49%)
AMD   107.42 (+1.53%)
T   27.59 (+1.70%)
F   14.25 (+3.41%)
ACB   6.38 (+7.23%)
DIS   179.10 (+1.76%)
PFE   43.77 (-0.39%)
BA   225.94 (+2.06%)
BAC   43.38 (+2.94%)
S&P 500   4,443.84 (-0.26%)
DOW   34,923.68 (+0.36%)
QQQ   369.69 (-0.98%)
AAPL   145.06 (-1.27%)
MSFT   293.69 (-1.89%)
FB   351.48 (-0.42%)
GOOGL   2,824.56 (-0.69%)
TSLA   794.40 (+2.58%)
AMZN   3,379.81 (-1.33%)
NVDA   215.16 (-2.56%)
BABA   148.24 (+2.18%)
NIO   36.35 (+2.74%)
CGC   14.72 (+5.82%)
GE   105.97 (+2.09%)
MU   75.15 (+1.49%)
AMD   107.42 (+1.53%)
T   27.59 (+1.70%)
F   14.25 (+3.41%)
ACB   6.38 (+7.23%)
DIS   179.10 (+1.76%)
PFE   43.77 (-0.39%)
BA   225.94 (+2.06%)
BAC   43.38 (+2.94%)
S&P 500   4,443.84 (-0.26%)
DOW   34,923.68 (+0.36%)
QQQ   369.69 (-0.98%)
AAPL   145.06 (-1.27%)
MSFT   293.69 (-1.89%)
FB   351.48 (-0.42%)
GOOGL   2,824.56 (-0.69%)
TSLA   794.40 (+2.58%)
AMZN   3,379.81 (-1.33%)
NVDA   215.16 (-2.56%)
BABA   148.24 (+2.18%)
NIO   36.35 (+2.74%)
CGC   14.72 (+5.82%)
GE   105.97 (+2.09%)
MU   75.15 (+1.49%)
AMD   107.42 (+1.53%)
T   27.59 (+1.70%)
F   14.25 (+3.41%)
ACB   6.38 (+7.23%)
DIS   179.10 (+1.76%)
PFE   43.77 (-0.39%)
BA   225.94 (+2.06%)
BAC   43.38 (+2.94%)
NASDAQ:JNCE

Jounce Therapeutics Stock Forecast, Price & News

$8.30
+0.11 (+1.34 %)
(As of 09/27/2021 12:17 PM ET)
Add
Compare
Today's Range
$8.06
$8.46
50-Day Range
$5.04
$8.73
52-Week Range
$5.03
$14.84
Volume6,439 shs
Average Volume479,355 shs
Market Capitalization$425.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.11
30 days | 90 days | 365 days | Advanced Chart
Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Jounce Therapeutics logo

About Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.97 out of 5 stars

Medical Sector

619th out of 1,352 stocks

Biological Products, Except Diagnostic Industry

98th out of 195 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

Is Jounce Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Jounce Therapeutics stock.
View analyst ratings for Jounce Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Jounce Therapeutics?

Wall Street analysts have given Jounce Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Jounce Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Jounce Therapeutics' next earnings date?

Jounce Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.
View our earnings forecast for Jounce Therapeutics
.

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics, Inc. (NASDAQ:JNCE) posted its quarterly earnings results on Thursday, August, 5th. The company reported ($0.08) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.36) by $0.28. The firm had revenue of $25.37 million for the quarter, compared to analyst estimates of $9.48 million.
View Jounce Therapeutics' earnings history
.

How has Jounce Therapeutics' stock price been impacted by Coronavirus?

Jounce Therapeutics' stock was trading at $4.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, JNCE stock has increased by 92.8% and is now trading at $8.25.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for JNCE?

5 Wall Street analysts have issued 1-year target prices for Jounce Therapeutics' shares. Their forecasts range from $10.00 to $17.00. On average, they anticipate Jounce Therapeutics' share price to reach $14.25 in the next twelve months. This suggests a possible upside of 72.7% from the stock's current price.
View analysts' price targets for Jounce Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the following people:
  • Richard Murray, President, Chief Executive Officer & Director
  • Kimberlee Cobleigh Drapkin, Chief Financial Officer & Treasurer
  • Elizabeth G. Trehu, Chief Medical Officer (LinkedIn Profile)
  • Dmitri Wiederschain, Chief Scientific Officer
  • Stephen Farrand, Chief Technical Officer

What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO?

45 employees have rated Jounce Therapeutics CEO Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among Jounce Therapeutics' employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jounce Therapeutics own?

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include TRV GP II LLC (8.68%), BlackRock Inc. (4.80%), Vanguard Group Inc. (2.75%), Dimensional Fund Advisors LP (2.40%), FMR LLC (1.54%) and Credit Suisse AG (1.07%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray and Rock Ventures Ii LP Third.
View institutional ownership trends for Jounce Therapeutics
.

Which institutional investors are selling Jounce Therapeutics stock?

JNCE stock was sold by a variety of institutional investors in the last quarter, including TRV GP II LLC, Victory Capital Management Inc., Wells Fargo & Company MN, Citadel Advisors LLC, Schonfeld Strategic Advisors LLC, AXA S.A., Bank of America Corp DE, and State of Wisconsin Investment Board. Company insiders that have sold Jounce Therapeutics company stock in the last year include Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray, and Rock Ventures Ii LP Third.
View insider buying and selling activity for Jounce Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Jounce Therapeutics stock?

JNCE stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Congress Asset Management Co. MA, Geode Capital Management LLC, Northern Trust Corp, Dimensional Fund Advisors LP, JPMorgan Chase & Co., and Marshall Wace LLP.
View insider buying and selling activity for Jounce Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $8.25.

How much money does Jounce Therapeutics make?

Jounce Therapeutics has a market capitalization of $422.66 million and generates $62.34 million in revenue each year. The company earns $-43,840,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis.

How many employees does Jounce Therapeutics have?

Jounce Therapeutics employs 128 workers across the globe.

What is Jounce Therapeutics' official website?

The official website for Jounce Therapeutics is www.jouncetx.com.

Where are Jounce Therapeutics' headquarters?

Jounce Therapeutics is headquartered at 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 259-3840 or via email at [email protected].


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.